[Alpha Tau in GlobeNewswire] Alpha Tau announces the acceptance in major peer-reviewed journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of two landmark pre-clinical studies demonstrating significant potential synergies between the Alpha DaRT treatment and standard-of-care immunotherapy, chemotherapy and anti-angiogenic therapy

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”) (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today.

Read more here.